NCT04527198

Brief Summary

The purpose of this study is to determine the prevalence of brainstem dysfunction in critically ill ventilated and deeply sedated patients hospitalized in the Intensive Care Unit (ICU) for a SARS-CoV-s2 infection.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for not_applicable covid19

Timeline
Completed

Started Sep 2020

Shorter than P25 for not_applicable covid19

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 2, 2020

Completed
3 months until next milestone

First Posted

Study publicly available on registry

August 26, 2020

Completed
19 days until next milestone

Study Start

First participant enrolled

September 14, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

March 4, 2026

Status Verified

March 1, 2026

Enrollment Period

4 months

First QC Date

June 2, 2020

Last Update Submit

March 2, 2026

Conditions

Keywords

Brainstem dysfunctionDeliriumAwarenessArousalDysautonomiaAutonomic systemSARS-COV-2COVID-19sedationmechanical ventilationEEGEKG

Outcome Measures

Primary Outcomes (1)

  • Brainstem dysfunction prevalence

    Clinical cranial nerves anomalies using validated scale (BRASS score- ranges from 0 to 7 - ) in deeply sedated patient (RASS \<-3)

    At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessation

Secondary Outcomes (17)

  • Brainstem dysfunction prevalence after sedation weaning

    Day 4 to day 7 after sedation weaning

  • Link between brainstem dysfunction and clinical dysautonomia

    At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessationn

  • Link between brainstem dysfunction and clinical dysautonomia after sedation weaning

    4 to 7 days after sedation weaning

  • Characterization of brainstem dysfunction in COVID-19 patients: EEG power

    At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessation

  • Characterization of brainstem dysfunction in COVID-19 patients: EEG power after sedation weaning

    Day 4 to day 7 after sedation weaning.

  • +12 more secondary outcomes

Study Arms (1)

group 1

EXPERIMENTAL

Major patients, admitted in intensive care for a SARS-CoV-2 infection and requiring mechanical ventilation and deep sedation (with or without neuromuscular blockade)

Diagnostic Test: Brainstem Responses Assessment Sedation Score (BRASS)Diagnostic Test: Electroencephalogram with EKG lead

Interventions

It consists of a standardized evaluation of brainstem reflexes with a score of 1 attributed for absence of pupillary light reflex, cough reflex and the combined absence of grimace and oculocephalic reflex, a score of 2 for absent corneal reflex and a score of 3 for absent grimace in the presence of oculocephalic The resulting sum ranges from 0 to 7. It will be performed at two times points: a first time under sedation and a second time 3 to 5 days after sedation weaning.

group 1

A 20 minutes clinical (12 electrodes) EEG with an EKG lead will be performed a first time under sedation and a second time 3 to 5 days after sedation weaning. These EEG recordings will allow to measure the sympathic-parasympathetic ratio using spectral analysis of the EKG and also to measure quantitative markers of brain EEG activity (spectral power and connectivity in delta, theta, alpha, beta and gamma band; complexity).

Also known as: EEG
group 1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ICU hospitalization
  • Invasive mechanical ventilation
  • Deep sedation (RASS\<-3) \>12 hours
  • Positive SARS-COV-2 PCR

You may not qualify if:

  • History of neurologic disease (stroke, degenerative disease)
  • Pregnant women
  • Moribund patients
  • Minor patient
  • Major patient under guardianship or curatorship
  • Patient not affiliated to a social security scheme
  • Limitations and cessation of active therapies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hôpital Cochin

Paris, 75014, France

Location

HEGP

Paris, 75015, France

Location

Related Publications (2)

  • Rohaut B, Porcher R, Hissem T, Heming N, Chillet P, Djedaini K, Moneger G, Kandelman S, Allary J, Cariou A, Sonneville R, Polito A, Antona M, Azabou E, Annane D, Siami S, Chretien F, Mantz J, Sharshar T; Groupe d'Exploration Neurologique en Reanimation (GENER). Brainstem response patterns in deeply-sedated critically-ill patients predict 28-day mortality. PLoS One. 2017 Apr 25;12(4):e0176012. doi: 10.1371/journal.pone.0176012. eCollection 2017.

    PMID: 28441453BACKGROUND
  • Benghanem S, Cariou A, Diehl JL, Marchi A, Charpentier J, Augy JL, Hauw-Berlemont C, Gavaret M, Pene F, Mira JP, Sharshar T, Hermann B. Early Clinical and Electrophysiological Brain Dysfunction Is Associated With ICU Outcomes in COVID-19 Critically Ill Patients With Acute Respiratory Distress Syndrome: A Prospective Bicentric Observational Study. Crit Care Med. 2022 Jul 1;50(7):1103-1115. doi: 10.1097/CCM.0000000000005491. Epub 2022 Feb 9.

MeSH Terms

Conditions

COVID-19DeliriumAutonomic Nervous System Diseases

Interventions

Electroencephalography

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, NeurologicalDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosis

Study Officials

  • Bertrand HERMANN, MD, PhD

    Assistance Publique - Hôpitaux de Paris

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 2, 2020

First Posted

August 26, 2020

Study Start

September 14, 2020

Primary Completion

December 31, 2020

Study Completion

December 31, 2020

Last Updated

March 4, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations